A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol

Condition(s) targeted: Hyperlipidemia

Intervention: Atorvastatin (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Official title: A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin

Study design: Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Secondary outcome: The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening LDL-C < 6. 0 mmol/l Triglyceride level < 5. 0 mmol/l. Exclusion Criteria: Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.

Pfizer Investigational Site, Thun, BE, Switzerland

Pfizer Investigational Site, Langenthal, BE, Switzerland

Pfizer Investigational Site, Binningen, BL, Switzerland

Pfizer Investigational Site, Liestal, BL, Switzerland

Pfizer Investigational Site, Basel, BS, Switzerland

Pfizer Investigational Site, Basel, BS, Switzerland

Pfizer Investigational Site, Duedingen, FR, Switzerland

Pfizer Investigational Site, Onex, GE, Switzerland

Pfizer Investigational Site, Geneve, GE, Switzerland

Pfizer Investigational Site, Siebnen, SZ, Switzerland

Pfizer Investigational Site, Pfaeffikon, SZ, Switzerland

Pfizer Investigational Site, Malvaglia, TI, Switzerland

Pfizer Investigational Site, Lugano, TI, Switzerland

Pfizer Investigational Site, Melide, TI, Switzerland

Pfizer Investigational Site, Vezia, TI, Switzerland

Pfizer Investigational Site, Lugano, TI, Switzerland

Pfizer Investigational Site, Lausanne, VD, Switzerland

Pfizer Investigational Site, Prilly, VD, Switzerland

Pfizer Investigational Site, Ecublens, VD, Switzerland

Pfizer Investigational Site, Zug, ZG, Switzerland

Pfizer Investigational Site, Unteraegeri, ZG, Switzerland

Pfizer Investigational Site, Zuerich, ZH, Switzerland

To obtain contact information for a study center near you, click here.

Starting date: April 2005
Last updated: April 23, 2007